

Request for Proposal: Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL)

1. About GBT

GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage investigational product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease (SCD). GBT strives to incorporate patients' perspectives and needs into our corporate initiatives. To that end, we partner with the SCD community to provide support to 501 (c)(3) entities such as community-based organizations, patient advocacy groups, and umbrella organizations that represent collective patient voices and interests through sponsorships, grants, and charitable contributions.

2. Funding Overview:

GBT is pleased to announce the Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL). This new grant opportunity will support novel projects aimed at improving access to high quality healthcare among patients living with SCD in the United States. Healthcare delivery for these patients is typically suboptimal:

- In the United States, fewer than 10% of Medicaid and Medicare patients living with SCD see a hematologist at least once per year.^{1,2}
- SCD is responsible for an estimated 250,000 emergency department visits in the U.S. annually. The highest rate of emergency room 30-day readmissions is due to SCD. Approximately 20% of SCD patients in the U.S. receive most of their care in the emergency room.³
- The pediatric to adult transition for SCD patients is inadequate, leading to three-fold higher rates of mortality at age 18.⁴

In September 2018, GBT sponsored an Access to Care Summit for healthcare providers and other SCD stakeholders to discuss programs that are successfully working to address these significant gaps in healthcare delivery for both adults and children living with SCD. During the Summit, participants created draft roadmaps of these models to help disseminate best practices and to encourage the initiation of new SCD access-to-care programs.

The ACCEL Pilot Program builds on the momentum by providing funding for novel access-to-care pilot programs, with the goal of accelerating the development of promising programs with the potential over time to deliver high quality healthcare to people living with SCD. U.S.-based nonprofit organizations (501(c)(3)s) serving patients living with SCD and their families are eligible to apply. Individual grant awards may be up to fifty thousand (\$50,000) during a 12-month period. Suggested access-to-care pilots may include, but not are limited to:

Building a community outreach model from an existing SCD program to extend the reach of care:

A lack of clinicians knowledgeable in the provision of evidence-based, quality care is a key challenge for SCD patients. This type of proposal would focus on building a community outreach model to extend the reach of care. Examples could include telemedicine, community health outreach worker, patient

¹ Truven Claims Analysis. October 2016.

² Behou Claims & Script Analysis. January 2016.

³ Brousseau, D., Owens, P., Mosso, A., Panepinto, J., & Steiner, C. Acute Care Utilization and Rehospitalizations for Sickle Cell Disease. JAMA. 2010 (303) 13.

⁴ Paulukonis S., Eckman, J., Snyder, A., Hagar, W., Feuchtbaum, L., Zhou, M., Grant, A., & Hulihan, M. Defining Sickle Cell Mortality Using Population-Based Surveillance System, 2004 through 2008. Public Health Reports. 2016 (131).

navigator, or equivalent models aimed at patient education, SCD care plan adherence, and improving links between patients, caregivers, and providers.

Expanding available capacity by partnering with non-SCD stakeholders:

This type of proposal would focus on efforts aimed at improved access to healthcare specifically by building upon existing organizational capacity/infrastructure or by empowering providers in community settings to deliver quality care for patients with sickle cell disease. Examples could include: partnering with Federally Qualified Health Care Centers (FQHCs) or regional health networks to provide SCD-related care.

Improving transition between pediatric to adult care:

Improving the transition process for adolescents and young adults with sickle cell disease while focusing on a care model that includes multidisciplinary, comprehensive care that is accessible, well-coordinated and evidence-based protocol driven is critical to ensure optimal long-term outcomes. This type of proposal would address ways to overcome challenges with the transition from a pediatric care setting to adult SCD treatment centers or adult health care providers.

Innovative Nurse Practitioner outreach care models:

Nurse Practitioners (NPs) can play a pivotal role in the provision of SCD-related care. This type of proposal would focus on innovative approaches to NP-lead care that promote wellness and care coordination.

Innovative Training Programs:

Clinician training is critical to the prevention of long-term complications and improved long-term survival among SCD patients; however, many clinicians lack the necessary training to care for SCD patients. This type of proposal would focus on novel approaches to physician and other health care provider training on the management of SCD and SCD patients' needs.

3. Grant Proposal Application Deadline:

- **Applications must be submitted by 5:00pm Pacific Time on May 1, 2019.**

4. Eligibility Requirements:

To be considered for support, applicants must:

- Be a U.S.-based nonprofit organization dedicated to SCD and are exempt from taxation under section 501(c)(3) of the Internal Revenue Code. Proof of tax exempt status will be required.
- Have the organizational capacity needed to manage the proposed project's timeline and deliverables.
- Submit an application by the stated deadline of 5:00pm PST on May 1, 2019. Applications received after the deadline will not be evaluated.
- Collaborations between two or more entities are permitted but not required.
- Only one grant proposal application per organization will be considered.

5. Award Amount & Number of Awards:

- A grant award may be up to but not exceeding fifty thousand dollars (\$50,000).
- Up to three proposals will be funded.
- All materials submitted to GBT related to this request for proposal will not be returned and will become the property of GBT.

6. Funding Restrictions:

The following are outside the purview of this funding opportunity:

- Capital campaigns, building construction, employee benefits, or fundraising (does not preclude seeking funds from other sponsors)
- Projects or activities aimed solely at transportation to/from health care services
- Medical and scientific research (e.g., Investigator Sponsored Trials)
- Entertainment expenses
- Activities hosted at lavish facilities such as a spa or resort
- Funding market research or analysis to build a business plan
- While salaries exclusive of benefits for Community Health Outreach Workers or Patient Navigators is permitted, direct physician or other health care provider salaries/compensation is outside the purview of this program.

7. Evaluation Criteria:

Proposals will be reviewed by a panel comprised of GBT personnel and external stakeholders with expertise in the issues affecting people with SCD. Responses to questions or requirements identified in the application will form the basis of evaluation. The final decision and award(s) granted by GBT will be subject to the following key decision criteria about each application:

- SMART (specific, measurable, achievable, relevant, & timely) goals & objectives
- Strength of proposal and team responsible for completing work
- Highest potential impact to SCD patient care
- Degree of innovation of the approach
- Ability to execute on plan
- Evaluation methods and sustainability plan
- Budget

8. Grant funding period:

The funding period is 12 months from the date of award. Grant funds will be disbursed throughout the 12-month period based on completion of milestones specified in the proposal.

9. Required Grantee Reporting:

Grantees are required to submit quarterly progress reports during the funding period documenting milestone(s) achieved and funds used to date. Upon receipt and review of report, if milestones are met, the next installment of funding will be issued. A final report documenting project outcomes and use of funds is due 90 days after the termination date of the grant.

10. Proposal Preparation & Submission Guidelines:

All responses to this RFP must be in English with currency in USD. To submit a proposal, complete the ACCEL grant proposal application form and submit along with the required documentation listed below. Please visit gbt.com/patients/accel-grant-program/ to obtain an application form.

1. Cover letter written on your organization's letter head with the following information:
 - a. Formal request for funds
 - b. Description of the project for which you seek funding
2. Detailed scope of work including quarterly milestones
3. Biographical sketch of project lead and detailed narrative of key personnel including title, qualifications, role, and % FTE
4. Detailed line item budget that includes the following:
 - a. Minimal but essential permanent equipment directly relevant to the GBT grant
 - b. Supplies (broken down by subcategory, e.g., postage, print or training materials)
 - c. Indirect costs



- d. Other expenses relevant to the conduct of the grant's goals/intended outcomes
5. W-9 form (signed/dated not more than 1 year ago)
6. IRS tax determination letter of 501(c)(3) status

11. Supplemental Information:

While not required, supplemental information may be included in a proposal submission (e.g., letter/s of support). All supplemental materials must be submitted as appendices and be in PDF format.

12. Grant Award Letter:

All proposals which are awarded a grant will be required to sign a grant award letter agreeing to the terms upon which such grant has been provided. GBT does not have any obligations to a grant requestor until the parties have signed an award letter.

Applications must be emailed to patientadvocacy@gbt.com by 5pm Pacific Time on May 1, 2019. Proposals received after the deadline will not be evaluated.

Prohibition of Discrimination:

No person shall be excluded from participation in or denied benefits of any program or activity receiving financial support from GBT because of race, ethnic origin, religion, sex, disability, or sexual orientation.

Contact Information:

Inquiries concerning this funding opportunity are encouraged. Please contact patientadvocacy@gbt.com or call 1-800-741-9102 to request additional information or ask questions.